684 related articles for article (PubMed ID: 33773120)
1. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
[TBL] [Abstract][Full Text] [Related]
2. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
Nathan SD; Behr J; Collard HR; Cottin V; Hoeper MM; Martinez FJ; Corte TJ; Keogh AM; Leuchte H; Mogulkoc N; Ulrich S; Wuyts WA; Yao Z; Boateng F; Wells AU
Lancet Respir Med; 2019 Sep; 7(9):780-790. PubMed ID: 31416769
[TBL] [Abstract][Full Text] [Related]
3. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.
Hoeper MM; Simonneau G; Corris PA; Ghofrani HA; Klinger JR; Langleben D; Naeije R; Jansa P; Rosenkranz S; Scelsi L; Grünig E; Vizza CD; Chang M; Colorado P; Meier C; Busse D; Benza RL
Eur Respir J; 2017 Sep; 50(3):. PubMed ID: 28889107
[TBL] [Abstract][Full Text] [Related]
4. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
5. A focus on riociguat in the treatment of pulmonary arterial hypertension.
Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
[TBL] [Abstract][Full Text] [Related]
6. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
[TBL] [Abstract][Full Text] [Related]
7. The role of riociguat in combination therapies for pulmonary arterial hypertension.
Rahaghi FF; Trivieri MG; Sahay S
Respir Med; 2023 May; 211():107196. PubMed ID: 36889521
[TBL] [Abstract][Full Text] [Related]
8. Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
Kuroda K; Akagi S; Nakamura K; Sarashina T; Ejiri K; Ito H
Heart Lung Circ; 2020 Mar; 29(3):331-336. PubMed ID: 30773322
[TBL] [Abstract][Full Text] [Related]
9. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
[TBL] [Abstract][Full Text] [Related]
10. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.
Jaïs X; Brenot P; Bouvaist H; Jevnikar M; Canuet M; Chabanne C; Chaouat A; Cottin V; De Groote P; Favrolt N; Horeau-Langlard D; Magro P; Savale L; Prévot G; Renard S; Sitbon O; Parent F; Trésorier R; Tromeur C; Piedvache C; Grimaldi L; Fadel E; Montani D; Humbert M; Simonneau G
Lancet Respir Med; 2022 Oct; 10(10):961-971. PubMed ID: 35926542
[TBL] [Abstract][Full Text] [Related]
11. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
Gall H; Vachiéry JL; Tanabe N; Halank M; Orozco-Levi M; Mielniczuk L; Chang M; Vogtländer K; Grünig E
Lung; 2018 Jun; 196(3):305-312. PubMed ID: 29470642
[TBL] [Abstract][Full Text] [Related]
12. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Jansa P; Kim NH; Mayer E; Pulido T; Wang C; Colorado P; Fritsch A; Meier C; Nikkho S; Hoeper MM
Lancet Respir Med; 2016 May; 4(5):372-80. PubMed ID: 27067478
[TBL] [Abstract][Full Text] [Related]
13. Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial.
Kawakami T; Matsubara H; Shinke T; Abe K; Kohsaka S; Hosokawa K; Taniguchi Y; Shimokawahara H; Yamada Y; Kataoka M; Ogawa A; Murata M; Jinzaki M; Hirata K; Tsutsui H; Sato Y; Fukuda K
Lancet Respir Med; 2022 Oct; 10(10):949-960. PubMed ID: 35926544
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
15. Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh AM; Langleben D; Kilama MO; Fritsch A; Neuser D; Rubin LJ;
N Engl J Med; 2013 Jul; 369(4):330-40. PubMed ID: 23883378
[TBL] [Abstract][Full Text] [Related]
16. Practical management of riociguat in patients with pulmonary arterial hypertension.
Halank M; Tausche K; Grünig E; Ewert R; Preston IR
Ther Adv Respir Dis; 2019; 13():1753466619868938. PubMed ID: 31438774
[TBL] [Abstract][Full Text] [Related]
17. Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial.
Gladwin MT; Gordeuk VR; Desai PC; Minniti C; Novelli EM; Morris CR; Ataga KI; De Castro L; Curtis SA; El Rassi F; Ford HJ; Harrington T; Klings ES; Lanzkron S; Liles D; Little J; Nero A; Smith W; Taylor JG; Baptiste A; Hagar W; Kanter J; Kinzie A; Martin T; Rafique A; Telen MJ; Lalama CM; Kato GJ; Abebe KZ
Lancet Haematol; 2024 May; 11(5):e345-e357. PubMed ID: 38554715
[TBL] [Abstract][Full Text] [Related]
18. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
[TBL] [Abstract][Full Text] [Related]
19. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
McLaughlin VV; Jansa P; Nielsen-Kudsk JE; Halank M; Simonneau G; Grünig E; Ulrich S; Rosenkranz S; Gómez Sánchez MA; Pulido T; Pepke-Zaba J; Barberá JA; Hoeper MM; Vachiéry JL; Lang I; Carvalho F; Meier C; Mueller K; Nikkho S; D'Armini AM
BMC Pulm Med; 2017 Dec; 17(1):216. PubMed ID: 29282032
[TBL] [Abstract][Full Text] [Related]
20. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]